BioMarin Pharmaceuticals
BMRN
BMRN
556 hedge funds and large institutions have $13.7B invested in BioMarin Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 195 increasing their positions, 193 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
556
Holders Change
+4
Holders Change %
+0.72%
% of All Funds
8.8%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
80
Increased
195
Reduced
193
Closed
68
Calls
$116M
Puts
$70.2M
Net Calls
+$45.4M
Net Calls Change
+$25.6M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$208M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$68M |
| 3 |
O
OrbiMed
New York
|
+$60.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$56.5M |
| 5 |
HM
HealthCor Management
New York
|
+$47M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$253M |
| 2 |
ClearBridge Investments
New York
|
-$243M |
| 3 |
PA
Perceptive Advisors
New York
|
-$104M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$93.4M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$40.2M |
